These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 15459427

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS, Fayans EP.
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [Abstract] [Full Text] [Related]

  • 23. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
    Kotteas E, Alamara C, Kiagia M, Pantazopoulos K, Boufas A, Provata A, Charpidou A, Syrigos KN.
    Anticancer Res; 2008 Aug; 28(1B):529-33. PubMed ID: 18383897
    [Abstract] [Full Text] [Related]

  • 24. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J, Tripathy D.
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [Abstract] [Full Text] [Related]

  • 25. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.
    Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, Tomich C.
    Laryngoscope; 2006 Jan; 116(1):115-20. PubMed ID: 16481822
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dosing regimens and main adverse events of bisphosphonates.
    Body JJ.
    Semin Oncol; 2001 Aug; 28(4 Suppl 11):49-53. PubMed ID: 11544576
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Bisphosphonates for treatment and prevention of bone metastases.
    Michaelson MD, Smith MR.
    J Clin Oncol; 2005 Nov 10; 23(32):8219-24. PubMed ID: 16278476
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P.
    J Intern Med; 2008 Oct 10; 264(4):315-32. PubMed ID: 18823505
    [Abstract] [Full Text] [Related]

  • 34. The role of bisphosphonates in early breast cancer.
    Paterson AH.
    Oncologist; 2006 Oct 10; 11 Suppl 1():13-9. PubMed ID: 16971735
    [Abstract] [Full Text] [Related]

  • 35. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 36. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients.
    Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M, International Society of Geriatric Oncology.
    Eur J Cancer; 2007 Mar 01; 43(5):852-8. PubMed ID: 17258449
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Bisphosphonates in prostate carcinoma.
    Adami S.
    Cancer; 1997 Oct 15; 80(8 Suppl):1674-9. PubMed ID: 9362435
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.